Akari raises $2.26M via unsecured notes with 20% OID; Chairman Huh exchanges prior loan

Akari Therapeutics Plc

Issued notes with aggregate purchase price of $2,261,000 and principal amount of $2,826,250; maturity 12 months from closing.
Chairman Dr. Huh purchased $1,250,000 principal note for $1,000,000, paying $162,567 cash and cancelling $837,433 Peak Bio loan.
Extended expiration of Series A Warrants on 1,973,211 ADSs by 48 months from original expiry.
Paid Paulson Investment Company a 5% advisory fee ($70K) on ~$1.4M gross cash proceeds.
Notes are unsecured; proceeds used for general corporate purposes.

item 1.01item 1.02item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.